MCL Literature Feed

Quantifying the survival cost of delayed CAR T-cell reimbursement in Europe shows faster access for MCL patients would translate directly into more lives and life-years saved.

In a resource-limited setting, 12% of chemosensitive MCL patients progress by 3 months while awaiting autologous transplant, highlighting the need for prioritization and defining acceptable wait times.

This real-world study identifies key patient and systemic barriers limiting CAR-T therapy access for relapsed/refractory MCL, highlighting disparities between trial eligibility and clinical practice.

This real-world database analysis shows MCL patients treated at academic centers had significantly longer overall survival and higher trial participation, highlighting a major care disparity versus community settings.

This Delphi consensus provides a framework to overcome CAR-T referral barriers in MCL, emphasizing early patient identification and structured collaboration between centers to improve access and timeliness of therapy.

This study demonstrates the feasibility of administering brexucabtagene autoleucel in an outpatient setting for MCL, a significant shift that could improve patient convenience and reduce healthcare costs.

Real-world data on commercially insured B-cell NHL patients, including MCL, reveals a 48% relapse rate at 12 months post-CAR-T, with subsequent therapies incurring significant patient out-of-pocket costs.

A US claims analysis shows MCL treatment costs increase substantially with each line of therapy, driven by hospitalizations, underscoring the economic need for more effective, durable frontline regimens.

This review outlines strategies like non-viral vectors, allogeneic products, and point-of-care manufacturing to reduce CAR-T therapy costs, potentially increasing access for relapsed/refractory MCL patients.

In a real-world US analysis, relapsed/refractory MCL patients receiving CAR-T had longer treatment-free intervals and lower subsequent healthcare costs compared to standard therapies, supporting its earlier use.

This review contextualizes CAR-T therapy's established role in relapsed/refractory MCL, summarizing universal challenges such as toxicity, access, cost, and the need for effective salvage treatments post-progression.

Experienced nurses and advanced practice providers outline key considerations for implementing a successful outpatient lisocabtagene maraleucel CAR-T program, offering a practical framework for managing MCL patients.

A real-world Japanese study identified BTK inhibitor-based therapy and length of hospitalization as the main drivers of increased healthcare costs, providing crucial data for health economic planning.

A simulation model using 20 years of real-world data establishes a baseline for lifetime treatment trajectories, crucial for evaluating the cost-effectiveness of new targeted therapies in MCL.

Italian experts established consensus diagnostic and therapeutic pathways for MCL, standardizing care while highlighting ongoing debates on MRD utility, immunotherapy sequencing, and CAR-T versus bispecifics.

This systematic review of brexu-cel for relapsed/refractory MCL reveals conflicting cost-effectiveness conclusions across different countries, highlighting major uncertainties for health systems considering its adoption and reimbursement.

Real-world US Medicare data shows elderly MCL patients post-cBTKi have a dismal median OS of 9.4 months and high costs, highlighting the urgent need for effective therapies.

Outpatient autologous stem cell transplantation is a feasible consolidation strategy for advanced MCL in a low-income, Latin American setting, providing important real-world evidence for resource-constrained systems.

This paper outlines strategies for improved collaboration between community oncologists and authorized centers to overcome logistical and educational barriers, ensuring timely referral and access to CAR-T therapy for MCL.

This indirect comparison shows acalabrutinib has a superior safety profile to ibrutinib in relapsed/refractory MCL with similar efficacy, supporting its preferential use in this setting.